stockrowDenali Therapeutics Inc.
DNLI Healthcare Biotechnology
Denali Therapeutics Inc.’s revenue for fiscal 2023 (year ended December 2023) was $330.5 million, up 204.7% from fiscal 2022.
- Revenue
- −94.0%
- EPS
- +150.3%
- Free cash flow
- −11.8%
- Total debt
- −1.89%
Quarter to September 2026, against a year earlier
Follow DNLI
Alert me
Denali Therapeutics Inc. (DNLI) Return on invested capital
Denali Therapeutics Inc.'s return on invested capital over the twelve months to 30 September 2026 was −80.0%, up 149.2 percentage points from fiscal 2025 (−229.2%). Over the past ten years it has ranged from −539.0% (fiscal 2015) to 0.00% (fiscal 2023); the current reading is higher than 27% of that period. That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | −229.2% | (153.64) |
| FY2024 | −75.6% | (75.59) |
| FY2023 | 0.00% | 0.00 |
| FY2022 | 0.00% | 118.58 |
| FY2021 | −118.6% | (118.58) |
| FY2020 | 0.00% | 274.53 |
| FY2019 | −274.5% | (239.42) |
| FY2018 | −35.1% | 59.46 |
| FY2017 | −94.6% | (22.85) |
| FY2016 | −71.7% | 467.29 |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| ELVN Enliven Therapeutics, Inc. compare | 0.00% |
| TARS Tarsus Pharmaceuticals, Inc. compare | 0.00% |
| VRDN Viridian Therapeutics, Inc. compare | 0.00% |
| CELC Celcuity, Inc. compare | 0.00% |
| TLX Telix Pharmaceuticals Limited compare | 0.00% |
| VKTX Viking Therapeutics, Inc. compare | 0.00% |
| DNLI Denali Therapeutics Inc. | −80.0% |
| IDYA IDEAYA Biosciences, Inc. compare | −114.2% |
| DYN Dyne Therapeutics, Inc. compare | −1,956.3% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on DNLI
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement